Medical/Pharmaceuticals
Clarity receives US FDA Fast Track Designation for the treatment of metastatic castration-resistant prostate cancer patients with Cu-67 SAR-bisPSMA
SYDNEY, Feb. 19, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce thatthe Un...
2025-02-19 22:09
3523
Brexogen and BMI Korea Enter Strategic Technology Transfer Agreement for Exosome Therapeutics
Out-licenses BxC-I17e, Exosome-Based Therapeutics for New Indications
KRW 3 Billion Non-Refundable Upfront Payment + Milestone Payments +
Double-Digit Percentage Royalties
SEOUL, South Korea, Feb. 19, 2025 /PRNewswire/ -- Brexogen
2025-02-19 21:00
2711
Biosion, Inc. Appoints Kedan Lin, Ph.D., as Chief Development Officer and President of Biosion US
NEWARK, Del. and NANJING, China, Feb. 19, 2025 /PRNewswire/ -- Biosion, Inc. ("Biosion"), a global clinical-stage biotechnology company, is pleased to announce the appointment ofKedan Lin, Ph.D., as Chief Development Officer and President of Biosion US. With over two decades of expertise in biote...
2025-02-19 19:39
5326
AESOP Technology Unveils World's First Machine Learning Model to Combat Wrong-Site Surgery
SAN FRANCISCO, Feb. 18, 2025 /PRNewswire/ -- Wrong-site surgery (WSS), a critical "Never Event," represents a failure that should never occur in healthcare. Yet, due to underreporting, the true prevalence of these incidents remains obscured, jeopardizing patient safety and healthcare management.A...
2025-02-19 00:30
2621
VIVOZON Pharmaceutical Obtains MFDS Approval for UNAFRA Inj.: A Breakthrough Non-Opioid analgesic
SEOUL, South Korea, Feb. 18, 2025 /PRNewswire/ -- On February 17, VIVOZON Pharmaceutical announced that its non-opioid analgesic, UNAFRA Inj., was approved onDecember 12, 2024. (active ingredient: Opiranserin HCl), has received approval from the Ministry of Food and Drug Safety (MFDS). With this ...
2025-02-18 23:35
2315
HIMIAO Unveils BhairCx3™ Shine Factor ---- A Breakthrough in Feline Fur Care
XI'AN, China, Feb. 18, 2025 /PRNewswire/ -- The number of cat owners has surged dramatically in recent years. According to the 2025 White Paper onChina's Pet Industry, the number of pet cats inChina surpassed 71.53 million in 2024, accounting for 57.6% of all pet-owning households. However, as ca...
2025-02-18 22:15
2284
Transformation and rapid development of Visionary through the business integration
TORONTO, Feb. 18, 2025 /PRNewswire/ -- On January 26, 2025, Visionary's 2024 Annual Conference was held inToronto, celebrating the successful listing of Visionary's Pegasus New Energy Vehicles, SBS Green Energy, UBX FinTech, and American Precision Biotech on the U.S. OTC market. 2024 is a year of...
2025-02-18 22:00
3367
AHG Utilizes DeepSeek to Advance AI in Healthcare
QINGDAO, China, Feb. 18, 2025 /PRNewswire/ -- Akso Health Group (NASDAQ: AHG) (hereinafter referred to as "Akso Health," "the Company," or "we") announced today its integration of DeepSeek's advanced artificial intelligence technology. This initiative aims to further enhance AI-powered medical c...
2025-02-18 21:30
2810
Fangzhou Inc. integrates DeepSeek open-source AI Model to enhance Internet healthcare
SHANGHAI, Feb. 18, 2025 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in Internet healthcare solutions, announced the successful integration and local deployment of the DeepSeek-R1 open-source large language model onFebruary 8th. This upgrade is expected to yiel...
2025-02-18 21:16
2780
PharmaBlock Launches Commercial GMP Workshop 503 at Zhejiang Site
NANJING, China, Feb. 18, 2025 /PRNewswire/ -- PharmaBlock Sciences (Nanjing), Inc. (Stock code: 300725.SZSE) has announced the official launch of its commercial GMP Workshop 503 (W503) at PharmaBlock Zhejiang. The new workshop significantly enhances production capacity and further refines the hi...
2025-02-18 19:52
3232
WuXi Biologics Awarded Platinum Medal by EcoVadis Sustainability Rating for Second Consecutive Year
* Ranked among the top 1% of more than 150,000 companies across 185 countries * Trusted by global partners for strong sustainability commitment * Recognized as a leader in Green CRDMO, driving innovation for a healthier future SHANGHAI, Feb. 18, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio"...
2025-02-18 17:00
3315
CJ Bioscience to Present Preclinical Data on Inflammatory Bowel Disease Pipeline Candidate CJRB-201 at 'ECCO 2025'; Clinical Entry Targeted for 2026
* 'CJRB-201', a proprietary strain of Faecalibacterium with potent its anti-inflammatory effects, has demonstrated the strongest induction of regulatory T cells (Tregs) among analyzed strains. * Preclinical studies in multiple animal models confirm significant improvements in key disease indi...
2025-02-18 15:00
3066
Fosun Pharma Deeply Embraces AI, Self-developed PharmAID Decision Intelligence Platform Boosts Efficient Innovation
SHANGHAI, Feb. 17, 2025 /PRNewswire/ -- Nowadays, artificial intelligence (AI) technology is profoundly reshaping the landscape of the pharmaceutical and healthcare industry. As a global innovation-driven pharmaceutical and healthcare group, Fosun Pharma places great emphasis on the transforma...
2025-02-17 16:22
3811
IASO Bio Announces Acceptance of New Drug Application for Equecabtagene Autoleucel (FUCASO) by the Hong Kong Department of Health
SHANGHAI and NANJING, China and SAN JOSE, Calif., Feb. 14, 2025 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative cell therapies and biologics, today announced that theHong Kong ...
2025-02-14 22:30
5252
Bambusa Therapeutics Raises Approximately $90 Million in Series A Financing to Advance Next-generation Bispecific Antibodies for Immunology & Inflammation Diseases
BOSTON, Feb. 14, 2025 /PRNewswire/ -- Bambusa Therapeutics, Inc. (Bambusa), a biotechnology company developing bispecific antibodies for immunological and inflammatory (I&I) disorders, today announced the successful completion of its oversubscribed Series A financing of approximately $90 million....
2025-02-14 21:56
4401
Kexing Biopharm Obtained IND Approval for Its Self-developed GB05 from U.S. FDA
SHENZHEN, China, Feb. 14, 2025 /PRNewswire/ -- Kexing Biopharm Co., Ltd. (Stock Code: 688136.SH) recently announced that the Investigational New Drug Application (IND) of GB05, Human Interferon α1b Inhalation Solution, a self-developed product by the Company's wholly-owned subsidiary, Shenzhen K...
2025-02-14 21:00
6629
Harbour BioMed Announces Business Progress and Update
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Feb. 13, 2025 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on immunology and oncology, ...
2025-02-14 12:08
4516
Akeso Announces IND Acceptance for AK139, a Bispecific Antibody Targeting IL-4Rα and ST2 for Respiratory and Skin Diseases
HONG KONG, Feb. 13, 2025 /PRNewswire/ -- Akeso, Inc. (9926. HK) ("Akeso" or the "Company") is pleased to announce the acceptance of its Investigational New Drug (IND) application by the China National Medical Products Administration (NMPA) for AK139, a bispecific antibody targeting IL-4Rα and ST2...
2025-02-14 09:11
2528
Beyond Pouch Packaging: Hanmi Pharmaceutical Introduces a New Automated Vial Dispensing Solution in Canada and the United States
* Hanmi Pharmaceutical Global Business Headquarters Accelerates Expansion into Canadian and US Markets, Strengthening Collaboration with Distribution Partner McKesson * Introducing 'Countmate': A Customized Solution for Canadian and American Pharmacists Seeking Advanced Vial Preparation Techn...
2025-02-14 08:35
4045
Accropeutics Announces First Patient Dosed in Phase Ib Study of RIPK2 Inhibitor AC-101
NEW YORK, Feb. 13, 2025 /PRNewswire/ -- Accropeutics Inc. (Accropeutics), a clinical-stage biotechnology company pioneering the development of novel therapeutics that target molecular mechanisms of regulated cell death for immune mediated diseases, today announced the dosing of their first patien...
2025-02-13 18:53
3293
Week's Top Stories
Most Reposted
Hong Leong Bank Unveils HLB opus Extended Exclusively by Private Invitation
[Picked up by 320 media titles]
2026-09-03 23:53
TEATER BESAR TAMAN ISMAIL MARZUKI SIMPLIFIES WIRELESS WORKFLOWS WITH SENNHEISER SPECTERA
[Picked up by 283 media titles]
2026-09-03 10:00
A Taste of Thailand: Discover the Spirit of the Elephant at Chang Thai
[Picked up by 282 media titles]
2026-09-03 10:00
From Micro-Weddings to Milestones: Celebrating Life's Special Moments at Four Seasons Resorts of Asia
[Picked up by 282 media titles]
2026-09-04 10:43
OGA 2026 OPENS WITH STRONGER FOCUS ON MARKET ACCESS, REGIONAL PROJECTS AND ENERGY OPPORTUNITIES
[Picked up by 276 media titles]
2026-09-04 01:35
Most Read
Hong Leong Bank Unveils HLB opus Extended Exclusively by Private Invitation
2026-09-03 23:53
9443
FinVolution and NUS Business School share project findings focusing on Financial Inclusion for Filipino Overseas Domestic Helpers at UN Global Compact BRI Summit
2026-09-04 13:11
7279
Physical AI Firm XTEND Set to Make NYSE Trading Debut: NYSE Content Update
2026-09-04 21:14
6491
